糖尿病性勃起功能障碍研究进展  

Advances in Diabetic Erectile Dysfunction

作　　者：黄淑妍[1] 陈澍[2] 凤仪萍[3] 

机构地区：[1]广州医学院第二附属医院老年病科,广东广州510260 [2]广州医学院第二附属医院内分泌科,广东广州510260 [3]广州医学院第二附属医院泌尿外科,广东广州510260

出　　处：《中华男科学杂志》2006年第2期178-180,182,共4页National Journal of Andrology

摘　　要：勃起功能障碍是糖尿病常见并发症。糖尿病性勃起功能障碍发病率为20％-75％。糖尿病引起的血管、神经病变，肌肉组织的改变导致勃起功能障碍。控制血糖、血压和血脂是糖尿病性勃起功能障碍治疗的基础。半数的糖尿病性勃起功能障碍患者用磷酸二酯酶-5抑制剂治疗有效，海绵体内注射血管活性剂有效率大于90％，阴茎假体植入手术适用于经其他治疗效果不满意的各种勃起功能障碍患者。Erectile dysfunction is common complication of diabetes mellitus. The incidence of diabetes mellitus induced erectile dysfunction（DMED） is 20% -75%. DMED appears to be due to vascular-neuropathic and corpus vavemosum smooth muscular damage. To control blood glucose, blood pressure and blood lipids is the basis of DMED therapy. In 50% of the patients with DMED, the phosphodiesterase 5 inhibitors is effective, while intracavemous pharmacotherapy is effective for more than 90%. Penile prosthesis implantation continues to be the treatment of choice in case of other therapy failure.

关 键 词：勃起功能障碍 糖尿病 发病机制 治疗 

分 类 号：R587.2[医药卫生—内分泌]